FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2093670557> ?p ?o ?g. }

• W2093670557 endingPage "130" @default.
• W2093670557 startingPage "1" @default.
• W2093670557 abstract "Background Acute coronary syndromes (ACSs) are life-threatening conditions associated with acute myocardial ischaemia. There are three main types of ACS: ST segment elevation myocardial infarction (STEMI), non-ST segment elevation myocardial infarction (NSTEMI) and unstable angina (UA). One treatment for ACS is percutaneous coronary intervention (PCI) plus adjunctive treatment with antiplatelet drugs. Dual therapy antiplatelet treatment [aspirin plus either prasugrel (Efient ® , Daiichi Sankyo Company Ltd UK/Eli Lilly and Company Ltd), clopidogrel or ticagrelor (Brilique ® , AstraZeneca)] is standard in UK clinical practice. Prasugrel is the focus of this review. Objectives The remit is to appraise the clinical effectiveness and cost-effectiveness of prasugrel within its licensed indication for the treatment of ACS with PCI and is a review of National Institute for Health and Care Excellence technology appraisal TA182. Data sources Four electronic databases (MEDLINE, EMBASE, The Cochrane Library, PubMed) were searched from database inception to June 2013 for randomised controlled trials (RCTs) and to August 2013 for economic evaluations comparing prasugrel with clopidogrel or ticagrelor in ACS patients undergoing PCI. Methods Clinical outcomes included non-fatal and fatal cardiovascular (CV) events, adverse effects of treatment and health-related quality of life (HRQoL). Cost-effectiveness outcomes included incremental cost per life-year gained and incremental cost per quality-adjusted life-year (QALY) gained. An independent economic model assessed four mutually exclusive subgroups: ACS patients treated with PCI for STEMI and with and without diabetes mellitus and ACS patients treated with PCI for UA or NSTEMI and with and without diabetes mellitus. Results No new RCTs were identified beyond that reported in TA182. TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel Thrombolysis in Myocardial Infarction 38) compared prasugrel with clopidogrel in ACS patients scheduled for PCI. No relevant economic evaluations were identified. Our analyses focused on a key subgroup of patients: those aged < 75 years who weighed > 60 kg (no previous stroke or transient ischaemic attack). For the primary composite end point (death from CV causes, non-fatal myocardial infarction or non-fatal stroke) statistically significantly fewer events occurred in the prasugrel arm (8.3%) than in the clopidogrel arm (11%). No statistically significant difference in major bleeding events was noted. However, there was a significant difference in favour of clopidogrel when major and minor bleeding events were combined (3.0 vs. 3.9%). No conclusions could be drawn regarding HRQoL. The results of sensitivity analyses confirmed that it is likely that, for all four ACS subgroups, within 5–10 years prasugrel is a cost-effective treatment option compared with clopidogrel at a willingness-to-pay threshold of £20,000 to £30,000 per QALY gained. At the full 40-year time horizon, all estimates are < £10,000 per QALY gained. Limitations Lack of data precluded a clinical comparison of prasugrel with ticagrelor; the comparative effectiveness of prasugrel compared with ticagrelor therefore remains unknown. The long-term modelling exercise is vulnerable to major assumptions about the continuation of early health outcome gains. Conclusion A key strength of the review is that it demonstrates the cost-effectiveness of prasugrel compared with clopidogrel using the generic price of clopidogrel. Although the report demonstrates the cost-effectiveness of prasugrel compared with clopidogrel at a threshold of £20,000 to £30,000 per QALY gained, the long-term modelling is vulnerable to major assumptions regarding long-term gains. Lack of data precluded a clinical comparison of prasugrel with ticagrelor; the comparative effectiveness of prasugrel compared with ticagrelor therefore remains unknown. Well-audited data are needed from a long-term UK clinical registry on defined ACS patient groups treated with PCI who receive prasugrel, ticagrelor and clopidogrel. Study registration This study is registered as PROSPERO CRD42013005047. Funding The National Institute for Health Research Health Technology Assessment programme." @default.
• W2093670557 created "2016-06-24" @default.
• W2093670557 creator A5011624664 @default.
• W2093670557 creator A5016824381 @default.
• W2093670557 creator A5032242852 @default.
• W2093670557 creator A5041932491 @default.
• W2093670557 creator A5046298845 @default.
• W2093670557 creator A5049004669 @default.
• W2093670557 creator A5055825567 @default.
• W2093670557 creator A5058647212 @default.
• W2093670557 creator A5068763092 @default.
• W2093670557 creator A5079771128 @default.
• W2093670557 date "2015-04-01" @default.
• W2093670557 modified "2023-09-27" @default.
• W2093670557 title "Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis" @default.
• W2093670557 cites W119348236 @default.
• W2093670557 cites W14452866 @default.
• W2093670557 cites W1553345686 @default.
• W2093670557 cites W158289124 @default.
• W2093670557 cites W1959846991 @default.
• W2093670557 cites W1964382651 @default.
• W2093670557 cites W1969346883 @default.
• W2093670557 cites W1971907780 @default.
• W2093670557 cites W1978913815 @default.
• W2093670557 cites W1979833321 @default.
• W2093670557 cites W1980550333 @default.
• W2093670557 cites W1985059672 @default.
• W2093670557 cites W1986587917 @default.
• W2093670557 cites W1991406984 @default.
• W2093670557 cites W1993576230 @default.
• W2093670557 cites W1995512032 @default.
• W2093670557 cites W2000634649 @default.
• W2093670557 cites W2001172262 @default.
• W2093670557 cites W2003774081 @default.
• W2093670557 cites W2004487122 @default.
• W2093670557 cites W2005726649 @default.
• W2093670557 cites W2006763294 @default.
• W2093670557 cites W2008458407 @default.
• W2093670557 cites W2010869933 @default.
• W2093670557 cites W2015077976 @default.
• W2093670557 cites W2015690038 @default.
• W2093670557 cites W2021789346 @default.
• W2093670557 cites W2022237719 @default.
• W2093670557 cites W2024115454 @default.
• W2093670557 cites W2030539192 @default.
• W2093670557 cites W2033164977 @default.
• W2093670557 cites W2033781779 @default.
• W2093670557 cites W2034436876 @default.
• W2093670557 cites W2034949637 @default.
• W2093670557 cites W2038039359 @default.
• W2093670557 cites W2041880672 @default.
• W2093670557 cites W2050683601 @default.
• W2093670557 cites W2054817104 @default.
• W2093670557 cites W2064944632 @default.
• W2093670557 cites W2069654811 @default.
• W2093670557 cites W2071244681 @default.
• W2093670557 cites W2074920129 @default.
• W2093670557 cites W2093904865 @default.
• W2093670557 cites W2096002945 @default.
• W2093670557 cites W2102393690 @default.
• W2093670557 cites W2105371720 @default.
• W2093670557 cites W2106146046 @default.
• W2093670557 cites W2110108344 @default.
• W2093670557 cites W2111440264 @default.
• W2093670557 cites W2115836576 @default.
• W2093670557 cites W2116769108 @default.
• W2093670557 cites W2118300357 @default.
• W2093670557 cites W2119790985 @default.
• W2093670557 cites W2119989848 @default.
• W2093670557 cites W2122962595 @default.
• W2093670557 cites W2126039149 @default.
• W2093670557 cites W2126980526 @default.
• W2093670557 cites W2127324981 @default.
• W2093670557 cites W2127448855 @default.
• W2093670557 cites W2133187714 @default.
• W2093670557 cites W2138058610 @default.
• W2093670557 cites W2138514916 @default.
• W2093670557 cites W2140501627 @default.
• W2093670557 cites W2140776066 @default.
• W2093670557 cites W2142403455 @default.
• W2093670557 cites W2144206796 @default.
• W2093670557 cites W2146453185 @default.
• W2093670557 cites W2148871205 @default.
• W2093670557 cites W2150086052 @default.
• W2093670557 cites W2150740314 @default.
• W2093670557 cites W2152823642 @default.
• W2093670557 cites W2153447053 @default.
• W2093670557 cites W2154796702 @default.
• W2093670557 cites W2156506897 @default.
• W2093670557 cites W2157833432 @default.
• W2093670557 cites W2159206603 @default.
• W2093670557 cites W2166650056 @default.
• W2093670557 cites W2166950143 @default.
• W2093670557 cites W2169387542 @default.
• W2093670557 cites W2170949977 @default.
• W2093670557 cites W2272962241 @default.
• W2093670557 cites W3030817736 @default.
• W2093670557 cites W311320695 @default.

• next